



Phage and Ribosome Display for Antibody Discovery and Optimization

Guest Editor:

Dr. Adinarayana Kunamneni

Division of Infectious Diseases,
Department of Internal Medicine,
Mayo Clinic, Jacksonville, FL
32224, USA

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious antibody leads have become competitive processes. Phage and ribosome display are ideal tools for the generation of such molecules and have already delivered an approved drug as well as a multitude of clinical candidates. Large libraries (up to 10^{15}) can be rapidly constructed, antibodies selected, and sequence space extensively explored by targeted mutagenesis techniques or by random mutagenesis throughout the antibody sequence.

This Special Issue of *Antibodies* will consider any submission associated with phage and ribosome display, whether it be its use for discovering novel antibodies, the development of new phage and ribosome display techniques, optimization, humanization and affinity maturation approaches, or its utilization in novel applications in diagnostics and therapeutics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry,
Technical University Munich,
Emil-Erlenmeyer-Forum 5, 85350
Freising-Weihenstephan,
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (Drug Discovery)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI